Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
ID: 356879Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $100K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356879

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-122.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases," aimed at supporting pilot projects that explore the roles of understudied proteins linked to rare diseases. The objective is to generate preliminary data and tools related to these proteins, which are associated with rare diseases affecting fewer than 200,000 individuals in the U.S., thereby facilitating innovative research that could lead to new drug targets and treatments. Eligible applicants include a wide range of institutions, including educational and nonprofit organizations, government entities, and small businesses, with funding available up to $100,000 for projects that can be completed within one year. Interested parties can find more information and apply by contacting NIH Grants Information at grantsinfo@nih.gov, with applications due by November 16, 2027.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-122.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting applications for pilot projects aimed at studying understudied proteins linked to rare diseases. This funding opportunity, titled "Pilot Projects Investigating Understudied Proteins Associated with Rare Diseases," is part of the R03 Small Grant Program and allows for projects that can be completed in one year with a budget of up to $100,000 in direct costs. The goal is to generate preliminary data on eligible understudied proteins, which are proteins with limited biological characterization that have known associations with rare diseases affecting fewer than 200,000 individuals in the U.S. Eligible applicants include various educational and nonprofit institutions, government entities, and small businesses. The funding mechanism aims to facilitate innovative research that identifies new drug targets and catalyzes further studies in translational science, directly contributing to the development of treatments for the estimated 10,000 rare diseases. Applications must provide evidence linking the proposed understudied protein to a rare disease and are encouraged to employ non-animal methodologies. The initiative reflects NIH's commitment to enhancing biomedical research that addresses critical gaps in understanding rare conditions related to the human proteome.
    Similar Opportunities
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)" aimed at supporting clinical projects that enhance readiness for clinical trials in rare diseases. This initiative seeks applications that focus on developing and testing biomarkers and clinical outcome measures, as well as defining the characteristics of rare diseases to facilitate the design of future clinical trials. The program is particularly important for addressing the needs of rare diseases affecting fewer than 200,000 individuals in the U.S., with a maximum budget of $275,000 for direct costs over a project period of up to two years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for July 20, 2028.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for preclinical proof of concept studies targeting rare diseases under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established preclinical models for therapeutic agents, including small molecules and biologics, with the goal of advancing projects toward Investigational New Drug (IND) applications. The funding is particularly significant as it addresses the unmet medical needs of approximately 30 million individuals in the U.S. affected by rare diseases, enhancing the likelihood of progressing novel therapies to clinical trials. The total funding available is up to $1,200,000 for FY26, with a maximum budget of $275,000 per two-year project. Interested applicants must submit their letters of intent by May 1, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at identifying new druggable targets for pain related to understudied proteins. This initiative invites pilot projects that focus on generating preliminary data on specific eligible proteins, particularly those with a PubMed score of less than 10, which are considered understudied and may lead to innovative pain treatments. The funding opportunity, which provides up to $100,000 for a one-year project, emphasizes the importance of diversity in applicant teams and requires coordination among grant recipients. Interested applicants should note that the application submission period begins on January 16, 2025, and clinical trials are not permitted under this grant. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Grants for New Investigators to Broaden Participation in Health-Related Research (R21 Clinical Trial Optional)." This initiative aims to support new investigators from diverse and underrepresented backgrounds in biomedical research, enabling them to conduct small-scale projects that align with the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and other participating institutes. The grants, with a maximum budget of $125,000 per year for a project period not exceeding three years, are intended to facilitate the transition of these researchers toward independence while addressing health disparities. Interested applicants must demonstrate that they have had less than $125,000 in direct costs from combined active research funding and can submit proposals starting in early 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-097.html.
    Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Expanding the Target Landscape by Drugging the Undruggable," aimed at supporting exploratory projects that target currently undruggable protein classes associated with intractable human diseases. Applicants are required to identify a relevant undruggable target class and propose innovative preclinical methods or agents to address treatment gaps, with a focus on developing strategies that cannot be tackled by existing therapeutic approaches. This initiative is crucial for advancing translational science and improving public health outcomes by fostering the development of novel treatments for conditions that currently lack effective therapies. Up to $275,000 is available for projects over a two-year period, with applications due by February 17, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Forecast for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Forecast for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)," aimed at small businesses engaged in innovative research on undruggable target classes associated with intractable human diseases. The initiative seeks applications that propose methods or agents capable of selectively modulating traditionally undruggable targets, such as intrinsically disordered proteins and RNA, through preclinical proof of concept studies. This funding is critical for advancing therapeutic strategies for diseases that are challenging to treat with conventional therapies. The estimated total program funding is $1,000,000, with three awards expected, and interested applicants should prepare for the application process, which is anticipated to open with a synopsis posted on August 15, 2025, and close on October 16, 2025. For further inquiries, potential applicants can contact Dr. Karlie Sharma at Karlie.sharma@nih.gov or by phone at 240-381-3118.
    Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)" aimed at small businesses. This initiative seeks to support research that utilizes and enhances the utility of various Common Fund data sets, with objectives including the promotion of pilot studies, development of analytical tools, and demonstration of the value of integrating these data resources to address biomedical research questions. The total estimated funding for this program is $4 million, with approximately 13 awards expected to be made. Interested applicants can reach out to George Papanicolaou at george.papanicolaou@nih.gov or by phone at 301-402-7617 for further information, with proposals due by November 19, 2025, and project start dates anticipated for July 1, 2026.
    Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)." This initiative aims to support innovative natural history studies that generate high-quality data to advance medical product development for rare diseases with significant unmet needs. The funding is crucial for addressing knowledge gaps and facilitating the development of treatments in this area. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with grant amounts reaching up to $600,000. The application deadline is February 8, 2028, and interested parties can contact Kimberly Pendleton at Kimberly.Pendleton@fda.hhs.gov for further information.